99mTc–meropenem as a potential SPECT imaging probe for tumor hypoxia

T. Sakr; M. Motaleb; I. Ibrahim

doi:10.1007/s10967-011-1481-4

Jump to Content

Journal of Radioanalytical and Nuclear Chemistry

Volume/Issue:: Volume 292: Issue 2

^99mTc–meropenem as a potential SPECT imaging probe for tumor hypoxia

Authors:

T. Sakr

T. Sakr Radioactive Isotopes and Generator Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

Search for other papers by T. Sakr in
Current site
Google Scholar
PubMed

M. Motaleb

M. Motaleb Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

Search for other papers by M. Motaleb in
Current site
Google Scholar
PubMed

, and

I. Ibrahim

I. Ibrahim Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

Search for other papers by I. Ibrahim in
Current site
Google Scholar
PubMed

View More View Less

Pages:: 705–710

Online Publication Date:: 19 Oct 2011

Publication Date:: 01 May 2012

Article Category:: Research Article

DOI:: https://doi.org/10.1007/s10967-011-1481-4

Keywords:: Meropenem; 99mTc; SPECT; Tumor; Imaging; Hypoxia

Restricted access

Abstract

Meropenem was successfully radiolabeled with ^99mTc in high labeling yield (92 ± 2%) and stability (~6 h). ^99mTc–meropenem showed high accumulation in tumor hypoxic tissue (4.193% injected dose/g organ). ^99mTc–meropenem showed high ability to differentiate the tumor tissue from inflamed or infected tissues in different mice models as its T/NT ratio ~4 in case of tumor mice model while T/NT ratio ~1 in case of inflamed mice model. So, ^99mTc–meropenem showed high selectivity in comparison with FDG-PET and ^99mTc-nitroimidazole analogues. Thus, ^99mTc–meropenem could be used as a selective potential imaging agent for diagnosis of tumor hypoxia.

Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://akjournals.com/abstract/journals/10967/292/2/article-p705.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully

Collapse
Expand

Journal of Radioanalytical and Nuclear Chemistry

Print ISSN:: 0236-5731

Online ISSN:: 1588-2780

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language	English
Size	A4
Year of Foundation	1968
Volumes per Year	1
Issues per Year	12
Founder	Akadémiai Kiadó
Founder's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher	Akadémiai Kiadó Springer Nature Switzerland AG
Publisher's Address	H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible Publisher	Chief Executive Officer, Akadémiai Kiadó
ISSN	0236-5731 (Print)
ISSN	1588-2780 (Online)